Physician profile
Ewa Mrozek
NPI 1972518314
$654.45
in general payments reported to CMS, 2019-2025
17 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $25.36 · 2021: $171 · 2022: $21.76 · 2024: $108 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173 · Education: $67.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.73 |
| Education | $67.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $127.82 | 2019 | |
| Amgen INC. | $113.95 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $58.25 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $52.02 | 2021-2025 | |
| Gilead Sciences, INC. | $39.93 | 2021-2025 | Trodelvy |
| Eisai INC. | $38.66 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $34.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $30.10 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $24.75 | 2024 | Alunbrig |
| Acceleron Pharma, INC. | $21.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.58 | 2021 | |
| Genzyme Corporation | $16.76 | 2021 | |
| Tolmar, INC. | $15.79 | 2025 | Rubraca |
| Pharmaand Gmbh | $15.79 | 2025 | Rubraca |
| Merck Sharp & Dohme LLC | $15.68 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.28 | 2021 | |
| Pfizer INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Mrozek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.